Emergent BioSolutions (EBS) Non-Current Debt (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Non-Current Debt of $573.6 million for Q1 2026, down 13.84% year-over-year from $665.7 million in Q1 2025, and little changed quarter-over-quarter from $572.1 million in Q4 2025.
Emergent BioSolutions (EBS) Non-Current Debt (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Non-Current Debt history runs 17 years deep, the most recent figure standing at $573.6 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 13.84% year-over-year to $573.6 million; the TTM figure through Mar 2026 stood at $573.6 million (down 13.84% YoY), while the FY2025 annual figure was $572.1 million, down 13.8% from the prior year.
- Non-Current Debt for Q1 2026 stood at $573.6 million, roughly flat from $572.1 million in the prior quarter.
- The five-year high for Non-Current Debt was $1.0 billion in Q3 2022, with the low at $446.5 million in Q4 2023.
- The 5-year median for Non-Current Debt is $693.1 million (2025), against an average of $691.1 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Debt sank 56.57% in 2023, then jumped 103.08% in 2024.
- Emergent BioSolutions' Non-Current Debt stood at $448.5 million in 2022, then fell by 0.45% to $446.5 million in 2023, then jumped by 48.65% to $663.7 million in 2024, then fell by 13.8% to $572.1 million in 2025, then advanced by 0.26% to $573.6 million in 2026.
- Business Quant data shows EBS's Non-Current Debt at $573.6 million in Q1 2026, $572.1 million in Q4 2025, and $693.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 589.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 589.70 Mn |
| Mar 31, 2026 | 573.60 Mn |
| Dec 31, 2025 | 572.10 Mn |
| Sep 30, 2025 | 693.10 Mn |
| Jun 30, 2025 | 700.00 Mn |
| Mar 31, 2025 | 665.70 Mn |
| Dec 31, 2024 | 663.70 Mn |
| Sep 30, 2024 | 700.80 Mn |
| Jun 30, 2024 | 863.80 Mn |
| Mar 31, 2024 | 909.20 Mn |
| Dec 31, 2023 | 446.50 Mn |
| Sep 30, 2023 | 448.20 Mn |
| Jun 30, 2023 | 909.30 Mn |
| Mar 31, 2023 | 447.70 Mn |
| Dec 31, 2022 | 448.50 Mn |
| Sep 30, 2022 | 1.03 Bn |
| Jun 30, 2022 | 832.70 Mn |
| Mar 31, 2022 | 841.10 Mn |
| Dec 31, 2021 | 849.60 Mn |
| Sep 30, 2021 | 858.00 Mn |